Hims & Hers Health Sees Unusually Large Options Volume (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually large options trading activity on Wednesday. Stock traders bought 322,282 call options on the company. This is an increase of 128% compared to the average daily volume of 141,619 call options.

Insider Activity at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $367,870.91. Following the sale, the insider directly owned 169,940 shares in the company, valued at approximately $6,238,497.40. The trade was a 5.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 23,090 shares of the stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80. Following the completion of the transaction, the chief financial officer directly owned 94,333 shares of the company’s stock, valued at $3,369,574.76. This trade represents a 19.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 80,463 shares of company stock worth $2,846,696 in the last ninety days. Company insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtus Advisers LLC acquired a new position in shares of Hims & Hers Health during the second quarter worth approximately $26,000. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health in the third quarter valued at approximately $28,000. Flagship Harbor Advisors LLC bought a new position in Hims & Hers Health in the 4th quarter worth approximately $28,000. Binnacle Investments Inc acquired a new position in Hims & Hers Health during the 3rd quarter worth $28,000. Finally, Bogart Wealth LLC lifted its holdings in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 5.9%

HIMS stock opened at $23.47 on Wednesday. The business has a fifty day moving average price of $24.31 and a 200 day moving average price of $37.75. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The stock has a market capitalization of $5.35 billion, a price-to-earnings ratio of 46.01, a P/E/G ratio of 4.24 and a beta of 2.55. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business’s revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.11 earnings per share. Analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its board has initiated a share buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to purchase up to 3% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Settlement & commercial partnership with Novo Nordisk ends recent patent fight and lets HIMS offer FDA‑approved Wegovy/Ozempic (including new pill formats) on its platform — this materially reduces legal risk and opens a new, high‑margin revenue stream. Read More.
• Positive Sentiment: Multiple analyst upgrades and higher price targets followed the Novo news (Needham to Buy, Citi/Deutsche Bank raised targets/ratings), which supports further upside if GLP‑1 sales ramp. Read More.
• Positive Sentiment: HIMS is expanding its digital‑care platform (new specialties, lab testing, international moves) — a broader service set increases addressable market and cross‑sell opportunities for new branded drug offerings. Read More.
• Neutral Sentiment: Extremely high short interest and recent rapid gains raise the possibility of short‑squeeze‑driven volatility; that can amplify upside but also produce sharp reversals. Monitor short interest and volume closely. Read More.
• Neutral Sentiment: Recent Q4/FY results showed an EPS beat but a slight revenue miss — fundamentals show growth but remain mixed; GLP‑1 revenue could change near‑term guidance if rollout scales. Read More.
• Negative Sentiment: An asset manager has trimmed/left positions, signaling some institutional caution despite the deal — this could limit sustained buying if sentiment cools. Read More.
• Negative Sentiment: A securities‑style investigation into officers and directors was announced earlier this month — while the Novo settlement reduces one legal risk, governance/claims risk remains a headline risk for investors. Read More.

Wall Street Analyst Weigh In

Several analysts recently commented on HIMS shares. Evercore set a $24.00 price target on Hims & Hers Health in a research note on Tuesday, February 24th. Citigroup raised Hims & Hers Health from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $13.25 to $24.00 in a report on Tuesday. Truist Financial restated a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Barclays dropped their target price on shares of Hims & Hers Health from $48.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 24th. Finally, Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Three investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and a consensus price target of $30.46.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.